MX2017015202A - Formulaciones liquidas de celecoxib para administracion oral. - Google Patents

Formulaciones liquidas de celecoxib para administracion oral.

Info

Publication number
MX2017015202A
MX2017015202A MX2017015202A MX2017015202A MX2017015202A MX 2017015202 A MX2017015202 A MX 2017015202A MX 2017015202 A MX2017015202 A MX 2017015202A MX 2017015202 A MX2017015202 A MX 2017015202A MX 2017015202 A MX2017015202 A MX 2017015202A
Authority
MX
Mexico
Prior art keywords
celecoxib
oral administration
liquid formulations
solution
insolubility
Prior art date
Application number
MX2017015202A
Other languages
English (en)
Spanish (es)
Inventor
Scott Kiel Jeffrey
Jeffrey Bryant Thomas
Gerard Levasseur Richard
Greg Thomas Hugh
Original Assignee
Codadose Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codadose Incorporated filed Critical Codadose Incorporated
Publication of MX2017015202A publication Critical patent/MX2017015202A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
MX2017015202A 2015-05-29 2016-05-24 Formulaciones liquidas de celecoxib para administracion oral. MX2017015202A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168012P 2015-05-29 2015-05-29
PCT/US2016/033937 WO2016196085A1 (en) 2015-05-29 2016-05-24 Liquid formulations of celecoxib for oral administration
US15/163,258 US20160346300A1 (en) 2015-05-29 2016-05-24 Liquid formulations of celecoxib for oral administration

Publications (1)

Publication Number Publication Date
MX2017015202A true MX2017015202A (es) 2018-07-06

Family

ID=57396976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015202A MX2017015202A (es) 2015-05-29 2016-05-24 Formulaciones liquidas de celecoxib para administracion oral.

Country Status (9)

Country Link
US (1) US20160346300A1 (https=)
EP (1) EP3302430A4 (https=)
JP (1) JP2018516279A (https=)
AU (1) AU2016270504A1 (https=)
BR (1) BR112017025527A2 (https=)
CA (1) CA2987388A1 (https=)
MX (1) MX2017015202A (https=)
RU (1) RU2017145602A (https=)
WO (1) WO2016196085A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016267685A1 (en) * 2015-05-28 2017-12-07 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
WO2022185338A1 (en) * 2021-03-05 2022-09-09 Alkem Laboratories Limited Stable oral suspension of celecoxib and method of preparation thereof
CN115737554B (zh) * 2022-11-28 2024-07-09 宜昌人福药业有限责任公司 一种氯巴占口服混悬剂的制备方法
WO2024142089A1 (en) * 2022-12-27 2024-07-04 Cipla Limited Injectable compositions of celecoxib

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145440A (en) * 1977-08-18 1979-03-20 The Upjohn Company Liquid suspension of an aluminum salt of ibuprofen
IN191512B (https=) * 2000-01-21 2003-12-06 Panacea Biotech
WO2001078724A1 (en) * 2000-04-18 2001-10-25 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
AU2002364146A1 (en) * 2001-12-20 2003-07-09 Pharmacia Corporation Pharmaceutical suspension for oral administration
AU2003238221A1 (en) * 2002-06-17 2003-12-31 Taro Pharmaceuticals U.S.A, Inc. Ibuprofen suspension
US20060148877A1 (en) * 2002-11-26 2006-07-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050266031A1 (en) * 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US20110183944A1 (en) * 2010-01-28 2011-07-28 Paul Ashton SUSTAINED-RELEASE NSAID/HMG CoA REDUCTASE INHIBITOR COMPOSITIONS
EP2906208B1 (en) * 2012-10-09 2019-01-30 Sears, Douglas Therapeutic treatment
CN103932977A (zh) * 2014-04-15 2014-07-23 江苏正大清江制药有限公司 一种塞来昔布制剂的制备方法

Also Published As

Publication number Publication date
WO2016196085A1 (en) 2016-12-08
BR112017025527A2 (pt) 2018-08-07
US20160346300A1 (en) 2016-12-01
RU2017145602A (ru) 2019-07-02
RU2017145602A3 (https=) 2019-11-25
AU2016270504A1 (en) 2017-12-14
EP3302430A4 (en) 2019-05-29
CA2987388A1 (en) 2016-12-08
EP3302430A1 (en) 2018-04-11
JP2018516279A (ja) 2018-06-21

Similar Documents

Publication Publication Date Title
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
CR20200152A (es) DERIVADOS DE INDOL MONO-O-DI-SUSTITUIDOS COMO INHIBIDORES DE LA REPLICACIÓN VIRAL DEL DENGUE (Divisonal 2017-0490)
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MX389592B (es) Moduladores alostericos positivos del receptor m1 muscarinico
MX2018011788A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
CR20200291A (es) Composiciones y métodos para el tratamiento de enfermedades metabólicas
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
NZ721780A (en) Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
EA201500669A1 (ru) Офтальмологическая фармацевтическая композиция для наружного применения, содержащая регорафениб
MX2018002821A (es) Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico.
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
EA201792170A1 (ru) Производные индола
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
EA201891027A1 (ru) Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение
MX2016017315A (es) Formas de dosificacion farmaceutica.
EA201600411A1 (ru) Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний
RU2013127881A (ru) Применение фармацевтической композиции на основе соли четвертичного фосфония и замещенного динитробензофуроксана для лечения пироплазмоза у собак и способ лечения
IN2013MU03838A (https=)
IN2014MU01179A (https=)
EA201891136A1 (ru) Фармацевтическая композиция, содержащая в качестве активного ингредиента производное 7-азаиндолин-2-она или его фармацевтически приемлемую соль